EfpeglenatideLong-acting GLP-1 receptor agonist
Efpeglenatide is a long-acting GLP-1 receptor agonist studied in type 2 diabetes. Its research includes cardiovascular and kidney outcomes in a high-risk population, extending the question beyond glucose or weight alone.
What is Efpeglenatide?
Efpeglenatide is a long-acting, exendin-based GLP-1 receptor agonist studied in type 2 diabetes. Its clinical programme includes outcomes beyond glucose control in a high-risk population. 1 2
How it works
GLP-1 receptor activation affects glucose-dependent insulin signalling and other processes involved in glucose and appetite regulation. The medicine’s duration reflects its engineered formulation. 1
Effects studied
What does the evidence show?
Randomised cardiovascular-outcome research; archived references retained
Extending an exendin-based signal
Efpeglenatide uses an engineered structure to prolong GLP-1 receptor activity. Like other medicines in this pathway, it affects glucose regulation and related physiology. Its identity should remain separate from other long-acting GLP-1 agents, even when their descriptions sound similar.
Why AMPLITUDE-O matters
The retained AMPLITUDE-O paper examines cardiovascular and renal outcomes in people with type 2 diabetes at elevated risk. This is a more direct test of important health events than assuming that a lower HbA1c or body weight must produce those benefits. Interpreting the findings requires knowing which events were measured and who took part.
Avoiding a class-wide shortcut
A result for efpeglenatide can inform understanding of the pathway, but it does not establish an identical effect for every GLP-1 medicine or every patient group. Likewise, a diabetes cardiovascular trial is not a direct study of general longevity in healthy adults. The result is most informative for the people and outcomes studied.
Clinical value includes access and tolerability
Gastrointestinal adverse effects, discontinuation and other treatment considerations influence how useful a medicine may be. Current authorisation and availability also require their own check; a completed trial does not itself put a product on the market. The research findings do not establish what is currently available for local prescribing.
Safety & status
Gastrointestinal adverse effects and treatment discontinuation are relevant to interpreting benefit. Trial results do not establish current product availability or suitability for someone without the studied condition. 2
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Does an outcomes trial mean the product is available locally?
No. Trial evidence and current country-specific authorisation or supply are separate questions.
Is this evidence for healthy people seeking longevity?
No. AMPLITUDE-O studied a defined diabetes population with high cardiovascular risk. 2
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Efpeglenatide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Efpeglenatide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Efpeglenatide · retained primary-paper lead Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.